A technology that can change the way women check their baby’s health is in the final stages of development. PulseNmore LTD, an Israeli startup is developing a handheld ultrasound device that can be connected to any smartphone for monitoring the growth of a fetus.
Lodo Therapeutics Corporation, a drug discovery and development company focused on identifying and producing unique, bioactive natural products directly from the microbial DNA sequence information contained in soil, today announced that it has formed a strategic drug discovery collaboration with Genentech, a member of the Roche Group.
Janssen Pharmaceuticals is eying a potential breakthrough in treating refractory major depressive disorder. The company plans to seek regulatory approval for its ketamine-based esketamine nasal spray this year and if given the green light it will be the first new approach for the indication in nearly 50 years.
It has been stated by the patients that Gilead concealed crucial information that the TDF drugs could trigger kidney and bone risks. A safer alternative in the form of TAF could have been incorporated while marketing Truvada and Atripla. The research into TAF was deliberately stopped and the drugs are not likely to be brought to the shelf in the near future.
The Government of the Democratic Republic of the Congo declared a new outbreak of Ebola virus disease (EVD) in Bikoro in Equateur Province today (8 May). The outbreak declaration occurred after laboratory results confirmed two cases of EVD.
The questionnaire raised queries on the basis of key parameters like empathy for healthcare providers, quality content and motivation for patients. However, qualities like credible scientific content and values not related to promotional activities emerged as strong criterion for building trust.
The US-Based MiMedx group's (a manufacturer of regenerative medicine) shares fell 20% after the federal prosecutors charged three healthcare professional for accepting bribes from Mimedx. Of these shares, 7.5% recovered when closing for the day.
With a view to augment business activities and help improve product outreach; a UK-based life sciences firm has raised £1.5 million.
With a view to widening the scope of treatment for ovarian cancer patients, EU regulators have greenlighted MSD’s Lynparza and stamped approval for a new dosing regimen and tablet formulation for AstraZeneca.
AstraZeneca is back at it again with asset sales. The company, which has taken some flak for a series of deals to offload asset rights, inked an agreement with Luye Pharma for legacy antipsychotic Seroquel and an extended-release version.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.